Gilead Sciences, Inc. (GILD) Stock Analysis
A live, multi-source view of Gilead Sciences, Inc. (GILD): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 17,000 employees · gilead.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Gilead Sciences, Inc. (GILD) had a market capitalization of $187.23B (forward 15.3), a dividend yield of 2.17% and a beta of 0.35; the shares traded in a 52-week range of $108.46 – $157.29 (30.3% over the year).
- Market cap
- $187.23B
- Enterprise value
- $208.51B
- Forward P/E
- 15.3
- PEG ratio
- 2.03
- Price / book
- 15.84
- EPS (trailing)
- $-2.66
- EPS (forward)
- $9.89
- Dividend yield
- 2.17%
- Payout ratio
- 43.4%
- Ex-dividend date
- 2026-09-15
- 52-week range
- $108.46 – $157.29
- 52-week change
- 30.3%
- Beta
- 0.35
- Average volume
- 7.1M
- Shares outstanding
- 1.24B
- Short % of float
- 1.87%
- Profit margin
- -10.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Gilead Sciences, Inc. (GILD) last closed at $144.81 (the last completed close before that scan).
Technicals at the scan: RSI 53 (neutral territory), price -0.8% versus its 20-day average, 20-day versus 50-day average spread +6.0%, MACD histogram -0.69.
Sentiment inputs: 83% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 72/100.
Next scheduled company event: in 18 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 6 buys and 1 sell of GILD; corporate insiders filed 0 buys and 18 sells (8 distinct filers, latest disclosure 2026-09-02). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Daniel Patrick O'day (0B/6S), Jeffrey Bluestone (0B/5S), Anthony Welters (0B/4S), Tommy Tuberville (3B/1S), Johanna Mercier (0B/2S), Jared Moskowitz (2B/0S). Who is trading what
RapidTradeView pick record
GILD has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Gilead Sciences, Inc. (GILD) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell GILD.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.